genryzon-igf1-titration

name

genryzon-igf1-titration

description

Titrate Genryzon (somatrogon, weekly long-acting growth hormone) dose in a paediatric GHD patient using serum IGF-1 SDS. Encodes the mandatory 4-days-post-dose sampling rule, the target SDS window, the 15% dose-reduction trigger, and the oral estrogen adjustment. Use when a clinician asks how to titrate somatrogon, when to sample IGF-1 on Genryzon, target IGF-1 SDS on weekly GH, what to do if IGF-1 is too high on somatrogon, IGF-1 rising on Genryzon, how to adjust GH dose in a girl started on oral OCP, or presents a paediatric GHD case on somatrogon with an IGF-1 value to interpret. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

Genryzon IGF-1 Titration

Adjust the weekly somatrogon dose using serum IGF-1 SDS. Sampling timing is the single most-often-wrong step — get that right first, then apply the SDS rule.

---

Step 1 — Draw the IGF-1 sample at the correct time

Always draw the IGF-1 sample exactly 4 days after the prior weekly dose.

Somatrogon has a pharmacokinetic profile such that IGF-1 peaks a few days post-dose and then falls. A sample taken 1 day post-dose overestimates; a sample taken 6–7 days post-dose underestimates. Only day-4 samples are interpretable against the reference range used by the monograph.

If the timing was wrong, repeat the sample at day 4 before titrating.

---

Step 2 — Compare against the age- and sex-specific reference

Target: IGF-1 SDS between −2 and +2 (aim close to 0 SDS).

Use the assay's own reference values for age AND sex. IGF-1 rises through puberty — a boy Tanner 4 has a much higher normal than a boy Tanner 1 of the same chronological age.

IGF-1 SDS	Interpretation
> +2	Above target — reduce dose by 15% (see Step 3)
−2 to +2 (ideal near 0)	On target — no change; continue current dose
Below target with poor growth velocity	Under-dosed OR check adherence, injection technique, thyroid function, glucocorticoid interference; consider dose escalation only after ruling those out
Below target with adequate growth velocity	May still be acceptable — do not over-treat to raise IGF-1 if the child is growing well

---

Step 3 — Reduce dose by 15% when IGF-1 SDS > +2

If IGF-1 SDS exceeds +2:

1. Calculate the current weekly dose (mg)
2. Reduce by 15% (new dose = current dose × 0.85)
3. Round to the nearest pen increment:
   • 24 mg pen → 0.2 mg increments
   • 60 mg pen → 0.5 mg increments
4. Re-check IGF-1 at the next planned visit (or sooner if clinically indicated), 4 days post-dose

More than one 15% reduction may be required — do not attempt a larger single reduction. Iterate.

Worked example: Weekly dose 24 mg → 24 × 0.85 = 20.4 mg → round to nearest 0.5 mg → 20.5 mg once weekly. Recheck IGF-1 (day 4 post-dose) at next visit. If still >+2, reduce again to ~17.5 mg.

---

Step 4 — Adjust for oral estrogen

Oral estrogen (including combined OCPs, HRT) reduces the IGF-1 response to growth hormone via first-pass hepatic effects on IGF-1 generation.

When a female patient starts oral estrogen:

• Re-check IGF-1 4 days post-dose after 6–8 weeks
• A higher somatrogon dose may be needed to keep IGF-1 in target range

When a female patient stops oral estrogen:

• Re-check IGF-1 similarly
• Dose may need to decrease to avoid crossing the +2 SDS threshold

Transdermal estrogen does not have the same first-pass effect — dose adjustment usually not required. If switching a patient from oral to transdermal, expect the somatrogon requirement to fall.

---

Step 5 — Rule out confounders before adjusting dose

Before treating an out-of-range IGF-1 as a dosing problem, exclude:

• Wrong sampling timing (not day 4 post-dose) — repeat
• Adherence issues (missed doses, wrong technique) — patient interview + demonstration
• Assay switch (different lab → different reference) — check reference range used
• Concurrent illness / acute inflammation — IGF-1 falls acutely
• Untreated hypothyroidism — blunts response → falsely low IGF-1
• Concurrent glucocorticoid (esp. ↑ dose) — inhibits GH effect → falsely low IGF-1
• Malnutrition or protein deficiency — falsely low IGF-1
• Puberty stage shift — the reference range changes; re-plot against current Tanner/bone age
• Started/stopped oral estrogen (Step 4)

---

Step 6 — Follow-up cadence

• Routine IGF-1 SDS review at 6–12 month intervals (more frequent during puberty)
• After every dose change, re-check IGF-1 at the next visit (minimum 8–12 weeks) — day 4 post-dose
• Track auxological outcomes in parallel: height velocity, weight, bone age, Tanner stage. IGF-1 is a tool, not the goal — growth velocity and eventual final height are

---

Guardrails

• Day-4-post-dose IGF-1 is non-negotiable — a sample drawn on any other day cannot be interpreted against the monograph target
• Never react to a single high IGF-1 without confirming timing was correct and without checking for acute confounders (illness, glucocorticoid pulse, recent illness)
• Do not exceed a 15% single-step reduction — the monograph specifies iterative 15% steps
• IGF-1 above +2 SDS is a safety trigger, not a cosmetic one — chronically supra-physiologic IGF-1 is associated with growth of subclinical neoplasms and other risks; treat the number seriously
• Do not raise dose above 0.66 mg/kg/week for a "faster growth" request — the monograph anchors dosing to weight, not to parental expectation
• Female patient started on OCP is a routine trigger for re-checking IGF-1 — flag this actively in every teenage girl's visit
• A single day-4 IGF-1 below −2 SDS in a growing child is not automatically an under-dose — re-verify against pubertal-stage-matched reference and confirm growth velocity is genuinely poor before increasing

---

Source

Pfizer Products India Pvt. Ltd. GENRYZON® (Somatrogon) Solution for Injection in Pre-filled Pen — Prescribing Information (India). LPD version 2022-0081166 (PfLEET 2022-0081166). Section 4.2 "Dose titration" and Section 4.5 "Drug Interactions — Oral oestrogen therapy".